R R

What Is Osimertinib?

Osimertinib is a prescription targeted cancer medication marketed under the brand name Tagrisso. It belongs to the epidermal growth factor receptor tyrosine kinase inhibitor class and is used to treat selected forms of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Depending on disease stage and treatment history, osimertinib can be prescribed after surgery, after chemoradiation, or for advanced or metastatic disease. It is taken orally and can be used alone or with chemotherapy in certain settings.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Osimertinib?

Osimertinib is a prescription targeted cancer medication marketed under the brand name Tagrisso. It belongs to the epidermal growth factor receptor tyrosine kinase inhibitor class and is used to treat selected forms of non-small cell lung cancer (NSCLC) with specific EGFR mutations. Depending on disease stage and treatment history, osimertinib can be prescribed after surgery, after chemoradiation, or for advanced or metastatic disease. It is taken orally and can be used alone or with chemotherapy in certain settings.

read more about osimertinib ...

Copy this HTML:

Copy HTML Copied!

How Does Osimertinib Work?

Osimertinib inhibits abnormal EGFR signaling that contributes to the growth and survival of certain lung cancer cells. It targets activating EGFR mutations, including exon 19 deletions and exon 21 L858R mutations, as well as the T790M resistance mutation. By blocking EGFR tyrosine kinase activity, osimertinib interferes with cellular pathways that stimulate tumor growth. Its activity depends on the cancer's genetic characteristics. Molecular testing is necessary to determine whether a patient's tumor has a mutation associated with an approved treatment indication.

What Types of Lung Cancer Does Osimertinib Treat?

Osimertinib is approved for adults with selected EGFR-mutated non-small cell lung cancers. These include adjuvant treatment following complete tumor resection and treatment of unresectable stage III disease that has not progressed after platinum-based chemoradiation. It is also approved for first-line treatment of certain locally advanced or metastatic EGFR-mutated cancers, including an option combined with pemetrexed and platinum-based chemotherapy. Another indication involves metastatic NSCLC with an EGFR T790M mutation after progression during or following EGFR inhibitor therapy. An oncologist selects treatment using approved molecular testing and disease characteristics.

How Should Osimertinib Be Taken?

The recommended osimertinib dose is generally 80 mg orally once daily, with or without food. Tablets should be swallowed whole when possible, although specific instructions exist for dispersing a tablet in noncarbonated water when swallowing is difficult. Treatment duration depends on the indication. Adjuvant treatment can continue for up to three years, while other settings follow different stopping criteria. Dose interruption or reduction may be necessary for certain adverse reactions. Patients should avoid changing their dose without guidance from the oncology team.

What Are the Side Effects and Warnings of Osimertinib?

Common adverse effects include diarrhea, rash, dry skin, nail changes, and mouth inflammation. Serious risks include interstitial lung disease or pneumonitis, heart muscle dysfunction, QT interval prolongation, severe skin reactions, and eye inflammation such as keratitis. Muscle inflammation with elevated creatine phosphokinase is also a recognized warning. Osimertinib can harm an unborn baby. New or worsening breathlessness, chest pain, fainting, muscle weakness, eye pain, or vision changes require prompt medical assessment.

Common Questions About Osimertinib

Is osimertinib the same as Tagrisso?

Yes. Tagrisso is the brand name for osimertinib, an EGFR-targeted medication used for selected non-small cell lung cancers.

Is osimertinib chemotherapy?

Osimertinib is a targeted tyrosine kinase inhibitor rather than traditional cytotoxic chemotherapy. It can be combined with chemotherapy in certain approved treatment settings.

How often is osimertinib taken?

Osimertinib is generally taken once daily at a dose of 80 mg. Treatment duration and dose adjustments depend on the cancer indication and tolerability.

Can osimertinib affect eyesight?

Yes. Osimertinib can cause eye inflammation, including keratitis. Patients with eye pain, redness, light sensitivity, or changes in vision should seek prompt medical assessment.

References

DailyMed - TAGRISSO (osimertinib) tablet, film coated. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5e81b4a7-b971-45e1-9c31-29cea8c87ce7. Date Accessed October 22, 2026.

Osimertinib. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548495/. Date Accessed October 22, 2026.

Osimertinib. MedlinePlus. https://medlineplus.gov/druginfo/meds/a616005.html. Date Accessed October 22, 2026.

Osimertinib. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/71496458. Date Accessed October 22, 2026.

Osimertinib Mesylate. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/drugs/osimertinib. Date Accessed October 22, 2026.